Tech Company Financing Transactions
Delinia Funding Round
Delinia, operating out of San Francisco, secured $35 million from Atlas Accelerator, Sofinnova Ventures and private investors.
Transaction Overview
Company Name
Announced On
9/15/2016
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors
Atlas Accelerator (Lead Investor) (David Grayzel)
Sofinnova Ventures (Lead Investor) (Henrijette Richter)
Proceeds Purpose
Delinia plans to use the capital raised through this financing to advance the lead program though clinical proof-of-concept.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
953 Indiana Street
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Delinia is a biotechnology company developing novel therapeutics for the treatment of autoimmune diseases. Delinia's lead program is a molecule that potentiates and expands Regulatory T Cells (Tregs), powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Saurabh Saha
Chief Scientific Officer
Jeffrey Greve
VP - Bus. Development
Lijun Wu
Browse more venture capital transactions:
Prev: 9/15/2016: BrightVolt venture capital transaction
Next: 9/15/2016: Hybrent venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs